Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University

home / authors / sagar-lonial-md-facp-winship-cancer-institute-of-emory-university

Articles

Influencing Factors to Initially Targeting BCMA in MM

Influencing Factors to Initially Targeting BCMA in MM

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

Ongoing Approaches Toward Targeting BCMA

Ongoing Approaches Toward Targeting BCMA

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

Next Steps for Use of Belantamab in Clinical Practice

Next Steps for Use of Belantamab in Clinical Practice

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 25th 2021

Read More

Management of Ocular Events From DREAMM-2 Regimen

Management of Ocular Events From DREAMM-2 Regimen

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 25th 2021

Read More

DREAMM-2 Trial Regimen Safety Profile

DREAMM-2 Trial Regimen Safety Profile

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 18th 2021

Read More

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 18th 2021

Read More

The Rationale for Targeting BCMA in Multiple Myeloma

The Rationale for Targeting BCMA in Multiple Myeloma

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
December 18th 2020

Read More

Treatment Approach for R/R Multiple Myeloma

Treatment Approach for R/R Multiple Myeloma

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
December 18th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need